Credit Suisse’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-5
| Closed | -$3 | – | 3271 |
|
|
2022
Q4 | $3 | Hold |
5
| – | – | ﹤0.01% | 3858 |
|
|
2022
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 4019 |
|
|
2022
Q2 | $0 | Sell |
5
-325,227
| -100% | -$136K | ﹤0.01% | 3890 |
|
|
2022
Q1 | $233K | Buy |
325,232
+1,463
| +0.5% | +$3.13K | ﹤0.01% | 3333 |
|
|
2021
Q4 | $732K | Buy |
323,769
+92,404
| +40% | +$252K | ﹤0.01% | 3552 |
|
|
2021
Q3 | $666K | Buy |
231,365
+130,774
| +130% | +$373K | ﹤0.01% | 3623 |
|
|
2021
Q2 | $380K | Sell |
100,591
-70,754
| -41% | -$238K | ﹤0.01% | 4000 |
|
|
2021
Q1 | $580K | Sell |
171,345
-457,201
| -73% | -$1.65M | ﹤0.01% | 3675 |
|
|
2020
Q4 | $1.76M | Sell |
628,546
-38,265
| -6% | -$112K | ﹤0.01% | 2925 |
|
|
2020
Q3 | $1.67M | Buy |
666,811
+455,630
| +216% | +$4M | ﹤0.01% | 2555 |
|
|
2020
Q2 | $2.87M | Buy |
211,181
+130,562
| +162% | +$1.35M | ﹤0.01% | 2099 |
|
|
2020
Q1 | $611K | Sell |
80,619
-23,800
| -23% | -$185K | ﹤0.01% | 2993 |
|
|
2019
Q4 | $660K | Sell |
104,419
-21,925
| -17% | -$104K | ﹤0.01% | 3404 |
|
|
2019
Q3 | $495K | Buy |
126,344
+22,610
| +22% | +$96.9K | ﹤0.01% | 3444 |
|
|
2019
Q2 | $501K | Buy |
103,734
+2,265
| +2% | +$12.9K | ﹤0.01% | 3403 |
|
|
2019
Q1 | $831K | Buy |
101,469
+6,183
| +6% | +$42.4K | ﹤0.01% | 3031 |
|
|
2018
Q4 | $527K | Buy |
95,286
+64,747
| +212% | +$507K | ﹤0.01% | 3225 |
|
|
2018
Q3 | $270K | Sell |
30,539
-15,387
| -34% | -$138K | ﹤0.01% | 3570 |
|
|
2018
Q2 | $458K | Sell |
45,926
-7,062
| -13% | -$70.7K | ﹤0.01% | 3467 |
|
|
2018
Q1 | $506K | Buy |
52,988
+8,298
| +19% | +$116K | ﹤0.01% | 3357 |
|
|
2017
Q4 | $664K | Buy |
44,690
+8,451
| +23% | +$140K | ﹤0.01% | 3275 |
|
|
2017
Q3 | $712K | Buy |
36,239
+12,838
| +55% | +$197K | ﹤0.01% | 3326 |
|
|
2017
Q2 | $336K | Buy |
+23,401
| New | +$297K | ﹤0.01% | 3396 |
|
|
2017
Q1 | – | Sell |
-20,182
| Closed | -$210K | – | 3795 |
|
|
2016
Q4 | $210K | Sell |
20,182
-122
| -0.6% | -$1.05K | ﹤0.01% | 3795 |
|
|
2016
Q3 | $183K | Sell |
20,304
-12,139
| -37% | -$103K | ﹤0.01% | 3835 |
|
|
2016
Q2 | $242K | Buy |
32,443
+18,042
| +125% | +$157K | ﹤0.01% | 3785 |
|
|
2016
Q1 | $130K | Buy |
14,401
+509
| +4% | +$4.13K | ﹤0.01% | 3781 |
|
|
2015
Q4 | $179K | Buy |
13,892
+2,906
| +26% | +$29.7K | ﹤0.01% | 3931 |
|
|
2015
Q3 | $106K | Sell |
10,986
-41,566
| -79% | -$381K | ﹤0.01% | 4091 |
|
|
2015
Q2 | $541K | Buy |
52,552
+24,801
| +89% | +$212K | ﹤0.01% | 3663 |
|
|
2015
Q1 | $309K | Buy |
27,751
+8,056
| +41% | +$85.8K | ﹤0.01% | 3845 |
|
|
2014
Q4 | $229K | Buy |
+19,695
| New | +$282K | ﹤0.01% | 4206 |
|
Other funds holding AKBA
AIM
MFS
Credit Suisse's AKBA Position: Q1 2023 in Review
Credit Suisse sold out of Akebia Therapeutics (AKBA) in Q1 2023, closing a stake of 5 shares — an estimated $3 sold.
Credit Suisse first reported a position in AKBA in Q4 2014 and held it in 32 quarters. The position peaked at $2.87M in Q2 2020. 65 funds tracked by Wall St. Rank hold AKBA as of Q1 2023.
- Credit Suisse reported no remaining Akebia Therapeutics position as of Q1 2023 after selling out during the quarter.
- Credit Suisse sold 5 Akebia Therapeutics shares in Q1 2023, an estimated $3.
- Credit Suisse first reported a position in Akebia Therapeutics in Q4 2014 and held it in 32 quarters.
- Credit Suisse's Akebia Therapeutics position peaked at $2.87M in Q2 2020.
- 65 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2023.
Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.